Sanofi vet Kather­ine Bowdish named CEO of PIC Ther­a­peu­tics; As the world Terns: Liv­er dis­ease biotech makes ex­ec­u­tive changes

PIC Ther­a­peu­tics hasn’t raised much mon­ey, yet. But the fledg­ling biotech has at­tract­ed a high-pro­file play­er to the helm.

The Boston-based biotech has hand­ed the reins to Kather­ine Bowdish as its pres­i­dent and CEO. Bowdish will al­so join the board of di­rec­tors of PIC. Bowdish joins from Sanofi where she served as VP and head of R&D strat­e­gy, as well as help­ing launch and lead Sanofi Sun­rise, a ven­ture in­vest­ment and part­ner­ing ve­hi­cle at Sanofi. Be­fore that, Bowdish held sev­er­al ex­ec roles at Per­me­on Bi­o­log­ics, Anaphore, Alex­ion Phar­ma­ceu­ti­cals and Pro­li­faron (ac­quired by Alex­ion).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Associate

Alexandria Real Estate Equities

San Diego, CA, USA